

Technical Data Sheet

BV711 Mouse Anti-Human CD182

Product Information

Material Number:	744199
Size:	50 µg
Clone:	6C6
Alternative Name:	CXCR2; CXCR-2; IL8RB; IL-8Rβ; Interleukin 8 receptor, beta; CDw128b
Reactivity:	Human (Tested in Development)
Isotype:	Mouse IgG1, λ
Immunogen:	Human CXCR2 Transfected Cell Line
Application:	Flow cytometry (Qualified)
Concentration:	0.2 mg/ml
Entrez Gene ID:	3579
Storage Buffer:	Aqueous buffered solution containing ≤0.09% sodium azide.
Regulatory Status:	RUO

Description

The 6C6 monoclonal antibody specifically binds to CD182. CD182 is also known as the interleukin-8 receptor B (IL-8RB), a G-protein-linked seven transmembrane domain protein, expressed on monocytes and granulocytes. It is also expressed on a subset of T cells. Both IL-8RA (CXCR1) and IL-8RB (CXCR2) are high affinity receptors for IL-8. IL-8 is an inflammatory cytokine which induces chemotaxis of neutrophils, basophils and T lymphocytes.

The antibody was conjugated to BD Horizon™ BV711 which is part of the BD Horizon Brilliant™ Violet family of dyes. This dye is a tandem fluorochrome of BD Horizon BV421 with an Ex Max of 405-nm and an acceptor dye with an Em Max at 711-nm. BD Horizon BV711 can be excited by the violet laser and detected in a filter used to detect Cy™5.5 / Alexa Fluor® 700-like dyes (eg, 712/20-nm filter). Due to the excitation and emission characteristics of the acceptor dye, there may be moderate spillover into the Alexa Fluor® 700 and PerCP-Cy5.5 detectors. However, the spillover can be corrected through compensation as with any other dye combination.

Preparation and Storage

Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze. The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. The antibody was conjugated with BD Horizon BV711 under optimal conditions that minimize unconjugated dye and antibody.

Recommended Assay Procedure

For optimal and reproducible results, BD Horizon Brilliant Stain Buffer should be used anytime two or more BD Horizon Brilliant dyes (including BD OptiBuild Brilliant reagents) are used in the same experiment. Fluorescent dye interactions may cause staining artifacts which may affect data interpretation. The BD Horizon Brilliant Stain Buffer was designed to minimize these interactions. More information can be found in the Technical Data Sheet of the BD Horizon Brilliant Stain Buffer (Cat. No. 563794).

Suggested Companion Products

Catalog Number	Name	Size	Clone
349202	Lysing Solution 10X Concentrate	100 NA	
564219	Human BD Fc Block™	50 mg	
554656	Stain Buffer (FBS)	500 mL	
554657	Stain Buffer (BSA)	500 mL	
563794	Brilliant Stain Buffer	100 Tests	
555899	Lysing Buffer	100 mL	
563044	BV711 Mouse IgG1, k Isotype Control	50 µg	X40

Product Notices

1. This antibody was developed for use in flow cytometry.
2. The production process underwent stringent testing and validation to assure that it generates a high-quality conjugate with consistent performance and specific binding activity. However, verification testing has not been performed on all conjugate lots.
3. Researchers should determine the optimal concentration of this reagent for their individual applications.
4. An isotype control should be used at the same concentration as the antibody of interest.
5. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
6. For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
7. Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
8. BD Horizon Brilliant Stain Buffer is covered by one or more of the following US patents: 8,110,673; 8,158,444; 8,575,303; 8,354,239.
9. BD Horizon Brilliant Violet 711 is covered by one or more of the following US patents: 8,110,673; 8,158,444; 8,227,187; 8,455,613; 8,575,303; 8,354,239.
10. Cy is a trademark of GE Healthcare.
11. Alexa Fluor® is a registered trademark of Life Technologies Corporation.

References

- Baggiolini M, Loetscher P, Moser B. Interleukin-8 and the chemokine family. *Int J Immunopharmacol.* 1995; 17(2):103-108.
- Barclay NA, Brown MH, Birkeland ML, et al, ed. *The Leukocyte Antigen FactsBook*. San Diego, CA: Academic Press; 1997; .
- Callard R, Gearing A. Callard R, Gearing A. *The Cytokine Facts Book*. San Diego: Academic Press; 1994; .
- Qin S, LaRosa G, Campbell JJ, et al. Expression of monocyte chemoattractant protein-1 and interleukin-8 receptors on subsets of T cells: correlation with transendothelial chemotactic potential. *Eur J Immunol.* 1996; 26(3):640-647.
- van Vugt MJ, van den Herik-Oudijk IE, van de Winkle JG. Binding of PE-CY5 conjugates to the human high-affinity receptor for IgG (CD64). *Blood.* 1996; 88(6):2358-2361.
- Wu L, Ruffing N, Shi X, et al. Discrete steps in binding and signaling of interleukin-8 with its receptor.. *J Biol Chem.* 1996; 271(49):31202-9.

BD Biosciences

bdbiosciences.com

United States
877.232.8995

Canada
888.268.5430

Europe
32.53.720.550

Japan
0120.8555.90

Asia Pacific
65.6861.0633

Latin America/Caribbean
0800.771.7157

For country contact information, visit bdbiosciences.com/contact

Conditions: The information disclosed herein is not to be construed as a recommendation to use the above product in violation of any patents. BD Biosciences will not be held responsible for a patent infringement or other violations that may occur with the use of our products. Purchase does not include or carry any right to resell or transfer this product either as a stand-alone product or as a component of another product. Any use of this product other than the permitted use without the express written authorization of Becton Dickinson and Company is strictly prohibited.

For Research Use Only. Not for use in diagnostic or therapeutic procedures. Not for resale.

©2020 BD. All rights reserved. Unless otherwise noted, BD, the BD Logo and all other trademarks are the property of Becton, Dickinson and Company or its affiliates.

